Boston Scientific Corporation
BSX
$105.41
$0.490.47%
NYSE
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 2.24% | 8.36% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 2.24% | 8.36% | |||
| Cost of Revenue | -0.54% | 12.00% | |||
| Gross Profit | 3.56% | 6.71% | |||
| SG&A Expenses | -0.93% | 3.20% | |||
| Depreciation & Amortization | -2.67% | 9.76% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -1.19% | 8.02% | |||
| Operating Income | 18.61% | 10.03% | |||
| Income Before Tax | 37.61% | -12.56% | |||
| Income Tax Expenses | 478.26% | -88.50% | |||
| Earnings from Continuing Operations | 19.57% | 19.83% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -50.00% | -- | |||
| Net Income | 19.08% | 20.68% | |||
| EBIT | 18.61% | 10.03% | |||
| EBITDA | 10.90% | 11.13% | |||
| EPS Basic | 19.05% | 20.35% | |||
| Normalized Basic EPS | 8.25% | 17.25% | |||
| EPS Diluted | 18.51% | 19.22% | |||
| Normalized Diluted EPS | 8.25% | 17.13% | |||
| Average Basic Shares Outstanding | 0.20% | 0.10% | |||
| Average Diluted Shares Outstanding | 0.19% | 0.19% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||